QT Prolongation and Anticancer Drugs: Is it a Cardiologist’s Worry? The Oncologist’s Point of View

Author(s): Francesca Aroldi, Tiziana Prochilo, Elena Bonini, Alberto Zaniboni

Journal Name: Reviews on Recent Clinical Trials

Volume 11 , Issue 3 , 2016

Become EABM
Become Reviewer
Call for Editor


Currently, many novel therapies are available for physicians treating cancer; some of them are associated with adverse cardiac events. One of the most worrisome cardiac event is QT prolongation, which is a risk factor for developing the potentially fatal torsade de pointe. Many classes of drugs, both anticancer and concomitant agents, are involved in this issue. We report a review of old and new commonly used agents with torsadogenic potential.

Keywords: Adverse cardiac events, cancer, QT prolongation, through QT study, torsade de point.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [260 - 265]
Pages: 6
DOI: 10.2174/1574887111666160226150650
Price: $65

Article Metrics

PDF: 31